医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Menicon, Azabu University, and Yokohama City University Identify the Glaucoma Susceptibility Gene SRBD1 in Dogs

2013年12月24日 PM06:25
このエントリーをはてなブックマークに追加


 

NAGOYA, Japan

Menicon announces that an article entitled, “Dogs and humans share a common susceptibility gene SRBD1 for glaucoma risk”, which presents the results of a study conducted by Menicon, Azabu University, and Yokohama City University (hereinafter designated as “this study”), was published in the scientific journal PLoS ONE.

Menicon conducted a joint study with Azabu University and Yokohama City University and found that Shiba Inu dogs and humans share a susceptibility gene for glaucoma.
To date, several reports on normal tension glaucoma have been published, thus prompting Menicon to conduct a joint study with Yokohama City University. Menicon paid attention to the fact that the incidence of glaucoma in Shiba Inu dogs was high. Through the cooperation of Azabu University, which stores blood samples of dogs with various diseases, susceptibility genes for glaucoma of dogs were investigated. The results of the study showed that SRBD1, which was also identified in humans, was strongly associated with glaucoma.

This study revealed that the risk of glaucoma was three-fold higher in Shiba Inu dogs and five-fold higher in Shih Tzu dogs with a mutated SRBD1 gene than in Shiba Inu and Shih Tzu dogs with the normal, unmutated gene.

It is significantly rare for humans and dogs to share a susceptibility gene for a disease. The findings of this study thus provide a method for predicting the risk for developing glaucoma. Meni-One Co., Ltd., a subsidiary company of Menicon, engaged in animal ophthalmology medical care, will strive to disseminate the major findings of this study to reduce the risk of glaucoma in future generations of Shiba Inu dogs. As the Shiba Inu is a globally recognized Japanese domestic breed, the company is highly dedicated to the promotion of healthy Shiba Inu dogs worldwide through genetic testing.

Lastly, further studies involving dogs may prove useful in the research of glaucoma in humans. Menicon is hopeful that this research will generate significant contributions to society.

About Menicon

Headquartered in Nagoya, Japan, and represented in over 80 countries, Menicon Co., Ltd. is the only contact lens company in the world dedicated to every aspect of the field from material development and lens design to manufacturing of lenses and lens care solutions. Menicon offers an expanding portfolio of innovative lenses, packaging and related products that maximize user comfort and convenience. The company is also the world’s largest producer of gas-permeable contact lenses.

For more information, contact Yoko Kido (presscontact@menicon-net.co.jp) and visit menicon.com

CONTACT

Menicon Co., Ltd.
Yoko Kido, +81-52-935-1187
General Manager
Mecenat
/ PR & Secretary Dept.
Liaison & Public Relations Division
presscontact@menicon-net.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品が米国臨床腫瘍学会(ASCO)と欧州血液学会(EHA)の年次総会でオンコロジーの広範なポートフォリオとパイプラインのデータを発表
  • ResMed赞助的研究显示,采用居家吸氧与居家无创通气相结合治疗COPD具有成本效益
  • 武田在美国临床肿瘤学会(ASCO)和欧洲血液学会(EHA)年会上重点介绍其强大的肿瘤产品阵容和后续产品线数据
  • AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn Health Economic Model
  • GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing